Paul Doetsch, PhD, professor of radiation oncology and biochemistry and associate director for basic research at Emory’s Winship Cancer Institute and Damien Brégeon, PhD, at Institut de Génétique et Microbiologie in Paris, have outlined the role this process – known as transcriptional mutagenesis – might play in tumor development in a Nature Reviews Cancer article published online February 24th and in the March 2011 print edition.
Paul Doetsch, PhD, of Emory University partnered with Damien Brégeon, PhD, of Institut de Génétique et Microbiologie in Paris on an article published in the March 2011 issue of Nature Reviews Cancer.
“The majority of human cells do not multiply continuously but are slow-replicating and devote a large part of their energy to transcription,” say the authors. “DNA damage can miscode at the damaged site and produce mutant transcripts. This process is transcriptional mutagenesis and could lead to the production of mutant proteins and may therefore be important in tumor development.”
Transcriptional mutagenesis occurs when cells with damaged DNA produce bad messages during transcription, which leads to the creation of mutant proteins. Scientists already have learned that some genetic damages may block the transcription process, which is a signal for DNA repair molecules to move in and correct the mistake. When certain types of DNA damage are present, however, the non-dividing cells are capable of continuing transcription through the damage despite the erroneous coding messages. This problem can be exacerbated when cells have defects for repairing DNA damage.
As Doetsch and Brégeon note, data on this process are accumulating in several laboratories around the world, and evidence is mounting that transcriptional mutagenesis could have an important role in tumor development and other biological outcomes, including the development of drug resistance. However, at this point there is not enough evidence to know the extent to which transcriptional mutagenesis is involved in tumor development.
“One will have to follow the progeny of a single cell to determine whether cancerous growth can be initiated by the transient expression of oncogenic proteins or the disruption of signaling pathways,” the authors say. “Future studies addressing these issues will provide additional insights into the mechanisms and consequences of transcriptional mutagenesis and further establish the role of this process in tumor development.”
The Robert W. Woodruff Health Sciences Center of Emory University is an academic health science and service center focusing on teaching, research, health care and public service.